Beam Therapeutics (BEAM) Insider Trading & Ownership $26.43 +1.38 (+5.51%) (As of 08:01 PM ET) Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Beam Therapeutics (NASDAQ:BEAM) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage4.20%Number OfInsiders Buying(Last 12 Months)0Number OfInsiders Selling(Last 12 Months)7Amount OfInsider Selling(Last 12 Months)$10.45 M Get BEAM Insider Trade Alerts Want to know when executives and insiders are buying or selling Beam Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address BEAM Insider Buying and Selling by Quarter Ad Porter & CompanyFinancial Prophecy The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold $3 billion of Amazon… it’s why Nvidia’s CEO just sold $713 million... and it’s why Zuckerberg just sold $1.3 billion in Meta stock. The financial establishment doesn’t want you to know about this… but a controversial new documentary just pulled back the curtain and exposed what’s really going on. It’s called The Final Frontier.Including the name of the #1 company to buy. Beam Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails11/6/2024Giuseppe CiaramellaPresidentSell51,110$26.36$1,347,259.60 10/14/2024Giuseppe CiaramellaPresidentSell51,110$26.27$1,342,659.70 10/1/2024Bethany J CavanaghSVPSell289$23.48$6,785.72 10/1/2024Christine BellonInsiderSell385$23.48$9,039.80 9/30/2024John M EvansCEOSell60,000$24.60$1,476,000.00 7/1/2024Amy SimonInsiderSell502$23.76$11,927.52 Financial Prophecy (Ad)The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold $3 billion of Amazon… it’s why Nvidia’s CEO just sold $713 million... and it’s why Zuckerberg just sold $1.3 billion in Meta stock. The financial establishment doesn’t want you to know about this… but a controversial new documentary just pulled back the curtain and exposed what’s really going on. It’s called The Final Frontier.Including the name of the #1 company to buy.6/27/2024John M EvansCEOSell60,000$24.50$1,470,000.00 4/1/2024Amy SimonInsiderSell7,157$32.13$229,954.41 4/1/2024Giuseppe CiaramellaPresidentSell4,534$32.12$145,632.08 4/1/2024John M EvansCEOSell18,102$32.13$581,617.26 4/1/2024Terry-Ann BurrellCFOSell5,446$32.12$174,925.52 3/28/2024John M EvansCEOSell60,000$33.86$2,031,600.00 2/13/2024Fmr LlcInsiderSell1,565$30.76$48,139.40 1/31/2024John M EvansCEOSell60,000$25.33$1,519,800.00 1/3/2024Christine BellonInsiderSell1,907$26.42$50,382.94 (Data available from 1/1/2013 forward) BEAM Insider Trading Activity - Frequently Asked Questions Who is on Beam Therapeutics's Insider Roster? The list of insiders at Beam Therapeutics includes Amy Simon, Bethany J Cavanagh, Christine Bellon, Fmr Llc, Giuseppe Ciaramella, John M Evans, and Terry-Ann Burrell. Learn more on insiders at BEAM. What percentage of Beam Therapeutics stock is owned by insiders? 4.20% of Beam Therapeutics stock is owned by insiders. Learn more on BEAM's insider holdings. Which Beam Therapeutics insiders have been selling company stock? The following insiders have sold BEAM shares in the last 24 months: Amy Simon ($318,277.21), Bethany J Cavanagh ($6,785.72), Christine Bellon ($68,288.54), Fmr Llc ($48,139.40), Giuseppe Ciaramella ($10,090,317.96), John M Evans ($7,235,447.17), and Terry-Ann Burrell ($3,096,052.98). How much insider selling is happening at Beam Therapeutics? Insiders have sold a total of 666,519 Beam Therapeutics shares in the last 24 months for a total of $20,863,308.98 sold. Beam Therapeutics Key ExecutivesMr. John M. Evans M.B.A. (Age 46)CEO & Director Compensation: $1.13M2 recent tradesDr. Giuseppe Ciaramella Ph.D. (Age 55)President Compensation: $955.55kDr. Christine P. Bellon J.D. (Age 58)Ph.D., Senior VP, Chief Legal Officer & Corporate Secretary Compensation: $680.08kDr. Amy Simon M.D. (Age 60)Chief Medical Officer Compensation: $715.58kDr. Feng Zhang Ph.D.Co-FounderDr. David R. Liu Ph.D.Co-FounderDr. J. Keith Joung M.D.Ph.D., Co-FounderDr. Manmohan Singh Ph.D.Chief Technology OfficerDr. Gopi Shanker Ph.D.Chief Scientific OfficerMs. Susan O'Connor (Age 60)Chief Human Resources Officer More Insider Trading Tools from MarketBeat Related Companies Repligen Insider Transactions Halozyme Therapeutics Insider Transactions Krystal Biotech Insider Transactions ADMA Biologics Insider Transactions Arcellx Insider Transactions CRISPR Therapeutics Insider Transactions Immunovant Insider Transactions Scholar Rock Insider Transactions Denali Therapeutics Insider Transactions ImmunityBio Insider Transactions Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Insiders Selling Into 3 Rallies: Investors Should Do the OppositeInsiders Bet Big on These Small Cap StocksHere’s Why Etsy Management Is Investing $1 Billion in BuybacksInsider Buying Signals Upside for These 3 StocksBig Buybacks Announced: 3 Stocks Insiders Are Banking On This page (NASDAQ:BEAM) was last updated on 11/25/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredDeFi Coin on Verge of Breakout!The blueprint for millionaires is here. Don't let this be the missed opportunity you regret for years. Crypto 101 Media | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Beam Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Beam Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
